Is less more with isotretinoin and acne?

Gurkirti Brar MD CCFP  Parbeer Grewal MD FRCP  Christina Korownyk MD CCFP

Clinical question
Is low-dose isotretinoin as effective and tolerable as conventional doses in the treatment of acne?

Bottom line
Studies show that acne improvement with low-dose (about 20 mg/d) isotretinoin is similar to that with conventional doses. Low-dose isotretinoin might reduce common side effects by 16% to 35%; it might also be associated with higher relapse rates, particularly with severe acne, possibly owing to lower total accumulated doses.

Evidence
• Three RCTs compared conventional with low dosing. For 24 weeks, 60 patients with moderate acne used low (0.25 to 0.4 mg/kg daily) or conventional doses (0.5 to 0.7 mg/kg daily). The low-dose group showed equivalent efficacy (acne grading and lesion counts); increased patient satisfaction (76% very satisfied vs 31%); and a higher (non-significant) 1-year relapse rate (18% vs 13%). For 20 weeks, 150 patients with treatment-resistant nodulocystic acne used 0.1, 0.5, or 1 mg/kg daily. There was equivalent improvement with all doses; 18-month relapse rates were 42%, 20%, and 10%, respectively. Lower doses reduced common side effects (chapped lips, dry skin, and epistaxis) by 16% to 35%. In 120 patients with mild to severe acne using high (1 mg/kg daily) or low (20 mg/d) doses on alternating days for 16 weeks, the low-dose group had a decrease in acne load (81% vs 95%) and fewer side effects. A large prospective study (638 patients with moderate acne; 20 mg/d for 24 weeks) reported “good results” in about 94% of patients, decreased incidence of side effects, and a 5% relapse rate at 4 years. Smaller observational studies (doses about 20 mg/d) support these findings; 2 studies report improved outcomes with a total cumulative dose of 120 mg/kg.

Context
• Isotretinoin is approved for the treatment of severe acne in patients aged 12 and older; the recommended dosage is 0.5 to 1 mg/kg divided into 2 doses daily for 4 to 5 months. In many studies lower-dose groups reach lower total accumulated doses than the higher-dose treatment arms do, which might partly explain higher relapse rates. Recommended laboratory monitoring includes triglyceride, cholesterol, and liver transaminase levels, and complete blood count.

• Although there are reports of mood changes, suicidal thoughts, and suicide, no causal relationship has been proven.

• Isotretinoin is teratogenic and pregnancy must be prevented 1 month before, during, and after treatment.

Implementation
Isotretinoin is used in patients with severe, nodulocystic acne that is refractory to other treatments (eg, oral antibiotics). It is generally believed a cumulative isotretinoin dose ranging from 120 to 150 mg/kg is most effective in inducing acne remission. If acne is less severe or if adverse effects are a concern, then a lower daily dose is a reasonable option. Handouts on acne and websites on oral isotretinoin can help patients understand treatment options. A 2009 RxFiles article, accompanied by a patient follow-up sheet, might be helpful to clinicians.

Dr Brar is a practising family physician in Edmonton. Dr Grewal is Assistant Clinical Professor in the Division of Dermatology, and Dr Korownyk is Associate Professor in the Department of Family Medicine, both at the University of Alberta in Edmonton.

Competing interests
None declared

The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

References

Tools for Practice articles in Canadian Family Physician (CFP) are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in CFP are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice@cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.